3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 1/2
1
Status
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
3
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
28
Lymphoma, Mantle-Cell
14
Lymphoma, Non-Hodgkin
8
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma
5
Leukemia, B-Cell
4
Multiple Myeloma
3
Lymphoma, B-Cell
3
Waldenstrom Macroglobulinemia
2
Recurrence
2
Pancreatic Neoplasms
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Prolymphocytic
2
Leukemia
2
Squamous Cell Carcinoma of Head and Neck
1
Part1: Advanced B-cell Malignancies
1
Ovarian Neoplasms
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, B-Cell, Marginal Zone
1
Leukemia, Hairy Cell
1
Immunoproliferative Disorders
1
Immune System Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Heart Failure
1
Glioblastoma
1
DLBCL
1
Interventions
Rituximab
43
Cyclophosphamide
26
fludarabine
15
ibrutinib
14
Vincristine
11
Prednisone
11
Doxorubicin
11
pirtobrutinib
10
Bendamustine Hydrochloride
10
obinutuzumab
9
polatuzumab vedotin
6
Inotuzumab Ozogamicin
6
tocilizumab
5
pembrolizumab
5
glofitamab
5
Gemcitabine
5
zanubrutinib
4
venetoclax
4
ublituximab
4
Lenalidomide
4
Brentuximab Vedotin
4
Antigens, CD19
4
tazemetostat
3
acalabrutinib
3
Everolimus
3
DTRMWXHS-12
3
veltuzumab
2
sepantronium
2
iberdomide
2
denileukin diftitox
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoma, B-Cell
×
acalabrutinib
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled
NCT06564038
2026-05-14
Soundtrack-E
AstraZeneca
Phase 1/2
Recruiting
408 enrolled
NCT04529772
2026-03-31
ESCALADE
Acerta Pharma BV
Phase 3
Active not recruiting
611 enrolled